Literature DB >> 26787899

Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.

Joseph D Dekker1, Daechan Park2, Arthur L Shaffer3, Holger Kohlhammer3, Wei Deng1, Bum-Kyu Lee1, Gregory C Ippolito2, George Georgiou2, Vishwanath R Iyer1, Louis M Staudt4, Haley O Tucker5.   

Abstract

High expression of the forkhead box P1 (FOXP1) transcription factor distinguishes the aggressive activated B cell (ABC) diffuse large B-cell lymphoma (DLBCL) subtype from the better prognosis germinal center B-cell (GCB)-DLBCL subtype and is highly correlated with poor outcomes. A genetic or functional role for FOXP1 in lymphomagenesis, however, remains unknown. Here, we report that sustained FOXP1 expression is vital for ABC-DLBCL cell-line survival. Genome-wide analyses revealed direct and indirect FOXP1 transcriptional enforcement of ABC-DLBCL hallmarks, including the classical NF-κB and MYD88 (myeloid differentiation primary response gene 88) pathways. FOXP1 promoted gene expression underlying transition of the GCB cell to the plasmablast--the transient B-cell stage targeted in ABC-DLBCL transformation--by antagonizing pathways distinctive of GCB-DLBCL, including that of the GCB "master regulator," BCL6 (B-cell lymphoma 6). Cell-line derived FOXP1 target genes that were highly correlated with FOXP1 expression in primary DLBCL accurately segregated the corresponding clinical subtypes of a large cohort of primary DLBCL isolates and identified conserved pathways associated with ABC-DLBCL pathology.

Entities:  

Keywords:  DLBCL; FOXP1; lymphoma

Mesh:

Substances:

Year:  2016        PMID: 26787899      PMCID: PMC4747717          DOI: 10.1073/pnas.1524677113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.

Authors:  Weimin Ci; Jose M Polo; Leandro Cerchietti; Rita Shaknovich; Ling Wang; Shao Ning Yang; Kenny Ye; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne; Olivier Elemento; Ari Melnick
Journal:  Blood       Date:  2009-03-23       Impact factor: 22.113

2.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

3.  An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming.

Authors:  Mathieu Gabut; Payman Samavarchi-Tehrani; Xinchen Wang; Valentina Slobodeniuc; Dave O'Hanlon; Hoon-Ki Sung; Manuel Alvarez; Shaheynoor Talukder; Qun Pan; Esteban O Mazzoni; Stephane Nedelec; Hynek Wichterle; Knut Woltjen; Timothy R Hughes; Peter W Zandstra; Andras Nagy; Jeffrey L Wrana; Benjamin J Blencowe
Journal:  Cell       Date:  2011-09-15       Impact factor: 41.582

4.  NIH Image to ImageJ: 25 years of image analysis.

Authors:  Caroline A Schneider; Wayne S Rasband; Kevin W Eliceiri
Journal:  Nat Methods       Date:  2012-07       Impact factor: 28.547

Review 5.  Pathogenesis of human B cell lymphomas.

Authors:  Arthur L Shaffer; Ryan M Young; Louis M Staudt
Journal:  Annu Rev Immunol       Date:  2012-01-06       Impact factor: 28.527

6.  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.

Authors:  Yibin Yang; Arthur L Shaffer; N C Tolga Emre; Michele Ceribelli; Meili Zhang; George Wright; Wenming Xiao; John Powell; John Platig; Holger Kohlhammer; Ryan M Young; Hong Zhao; Yandan Yang; Weihong Xu; Joseph J Buggy; Sriram Balasubramanian; Lesley A Mathews; Paul Shinn; Rajarshi Guha; Marc Ferrer; Craig Thomas; Thomas A Waldmann; Louis M Staudt
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

7.  Down-regulation of the forkhead transcription factor Foxp1 is required for monocyte differentiation and macrophage function.

Authors:  Can Shi; Masashi Sakuma; Toshifumi Mooroka; Alison Liscoe; Huiyun Gao; Kevin J Croce; Arjun Sharma; David Kaplan; David R Greaves; Yunmei Wang; Daniel I Simon
Journal:  Blood       Date:  2008-09-17       Impact factor: 22.113

8.  Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype.

Authors:  Elena Sebastián; Miguel Alcoceba; Ana Balanzategui; Luis Marín; Santiago Montes-Moreno; Teresa Flores; David González; M Eugenia Sarasquete; M Carmen Chillón; Noemí Puig; Rocío Corral; Emilia Pardal; Alejandro Martín; Eva González-Barca; M Dolores Caballero; Jesús F San Miguel; Ramón García-Sanz; Marcos González
Journal:  Am J Pathol       Date:  2012-09-11       Impact factor: 4.307

9.  ZBTB32 is an early repressor of the CIITA and MHC class II gene expression during B cell differentiation to plasma cells.

Authors:  Hye Suk Yoon; Christopher D Scharer; Parimal Majumder; Carl W Davis; Royce Butler; Wendy Zinzow-Kramer; Ioanna Skountzou; Dimitrios G Koutsonanos; Rafi Ahmed; Jeremy M Boss
Journal:  J Immunol       Date:  2012-07-30       Impact factor: 5.422

10.  Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas.

Authors:  Michael J Kluk; Bjoern Chapuy; Papiya Sinha; Alyssa Roy; Paola Dal Cin; Donna S Neuberg; Stefano Monti; Geraldine S Pinkus; Margaret A Shipp; Scott J Rodig
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

View more
  17 in total

1.  PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.

Authors:  Marién Pascual; María Mena-Varas; Eloy Francisco Robles; Maria-Jose Garcia-Barchino; Carlos Panizo; Sandra Hervas-Stubbs; Diego Alignani; Ainara Sagardoy; Jose Ignacio Martinez-Ferrandis; Karen L Bunting; Stephen Meier; Xavier Sagaert; Davide Bagnara; Elizabeth Guruceaga; Oscar Blanco; Jon Celay; Alvaro Martínez-Baztan; Noelia Casares; Juan José Lasarte; Thomas MacCarthy; Ari Melnick; Jose Angel Martinez-Climent; Sergio Roa
Journal:  Blood       Date:  2019-04-11       Impact factor: 22.113

2.  FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.

Authors:  Hanjun Li; Xiuguo Han; Shengbing Yang; Yongjie Wang; Yang Dong; Tingting Tang
Journal:  Oncogene       Date:  2021-03-14       Impact factor: 9.867

3.  MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome.

Authors:  ZhiJun Qiu; An-Ping Lin; Shoulei Jiang; Sara M Elkashef; Jamie Myers; Subramanya Srikantan; Binu Sasi; John Z Cao; Lucy A Godley; Dinesh Rakheja; Yingli Lyu; Siyuan Zheng; Muniswamy Madesh; Yuzuru Shiio; Patricia L M Dahia; Ricardo C T Aguiar
Journal:  Cell Chem Biol       Date:  2020-02-25       Impact factor: 8.116

4.  FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.

Authors:  Anja Mottok; Vindi Jurinovic; Pedro Farinha; Andreas Rosenwald; Ellen Leich; German Ott; Heike Horn; Wolfram Klapper; Michael Boesl; Wolfgang Hiddemann; Christian Steidl; Joseph M Connors; Laurie H Sehn; Randy D Gascoyne; Eva Hoster; Oliver Weigert; Robert Kridel
Journal:  Blood       Date:  2017-11-09       Impact factor: 22.113

5.  FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging.

Authors:  Hanjun Li; Pei Liu; Shuqin Xu; Yinghua Li; Joseph D Dekker; Baojie Li; Ying Fan; Zhenlin Zhang; Yang Hong; Gong Yang; Tingting Tang; Yongxin Ren; Haley O Tucker; Zhengju Yao; Xizhi Guo
Journal:  J Clin Invest       Date:  2017-02-27       Impact factor: 14.808

6.  Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses.

Authors:  Bin Luo; Lanshan Huang; Yongyao Gu; Chunyao Li; Huiping Lu; Gang Chen; Zhigang Peng; Zhenbo Feng
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

7.  N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.

Authors:  Philip J Brown; Duncan M Gascoyne; Linden Lyne; Hayley Spearman; Suet Ling Felce; Nora McFadden; Probir Chakravarty; Sharon Barrans; Steven Lynham; Dinis P Calado; Malcolm Ward; Alison H Banham
Journal:  Haematologica       Date:  2016-04-07       Impact factor: 9.941

Review 8.  New developments in the pathology of malignant lymphoma. A review of the literature published from January-April 2016.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2016-06-13       Impact factor: 0.196

9.  The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells.

Authors:  Martine van Keimpema; Leonie J Grüneberg; Esther J M Schilder-Tol; Monique E C M Oud; Esther A Beuling; Paul J Hensbergen; Johann de Jong; Steven T Pals; Marcel Spaargaren
Journal:  Haematologica       Date:  2016-12-01       Impact factor: 9.941

10.  FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.

Authors:  Kah Keng Wong; Duncan M Gascoyne; Elizabeth J Soilleux; Linden Lyne; Hayley Spearman; Giovanna Roncador; Lars M Pedersen; Michael B Møller; Tina M Green; Alison H Banham
Journal:  Oncotarget       Date:  2016-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.